Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)
Gagnière, C.; Bourrier, A.; Seksik, P.et al.
2018 • In Alimentary Pharmacology and Therapeutics, 48 (7), p. 713-722
REENAERS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)
Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008;135:1493-1499
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476
Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017;66:588-596
Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol. 2015;8:66-82
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet Lond Engl. 2008;372:67-81
Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:1385-1397;e10
Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:30-35
Abitbol Y, Laharie D, Cosnes J, et al. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohns Colitis. 2016;10:1179-1185
Cosnes J, Seksik P. Chapter 18: Computer database for patients with IBD. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease, 3rd Edition, Vol 1. China: PMPH-USA; 2011:117-124
Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-656
Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010;4:7-27
Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990
Sokol H, Seksik P, Carrat F, et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59:1363-1368
Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468
Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207-4
Singh H, Nugent Z, Yu BN, et al. Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153:430-438;e2
D'Haens G, Reinisch W, Colombel J-F, et al. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. J Crohns Colitis. 2017;11:680-689
D'Haens G, Reinisch W, Satsangi J, et al. Adalimumab long-term effectiveness in adalimumab-naïve patients with Crohn's disease: final data from PYRAMID registry. J Crohns Colitis. 2017;11:S256-S257
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREATTM registry. Am J Gastroenterol. 2012;107:1409-1422
Cruz-Knight W, Blake-Gumbs L. Tuberculosis: an overview. Prim Care. 2013;40:743-756
Baussano I, Nunn P, Williams B, et al. Tuberculosis among health care workers. Emerg Infect Dis. 2011;17:488-494
Ministére de la Santé Décret no 96-775 du 5 septembre 1996 relatif à la vaccination par le vaccin antituberculeux B.C.G. et modifiant le code de la santé publique (deuxième partie: Décrets en Conseil d'Etat). Journal Officiel de la République Fançaise, no 209, 7th September 1996: pp 13376,. http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000745045&fastPos=1&fastReqId=1013377053&categorieLien=id&oldAction=rechTexte
Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep. 2005;54:1-141
Members of the Ad Hoc Committee for the Guidelines for Preventing the Transmission for Tuberculosis in Canadian Health Care Facilities and Other Institutional Settings. Guidelines for preventing the transmission of tuberculosis in Canadian Health Care Facilities and other institutional settings. Can Commun Dis Rep Releve Mal Transm Au Can. 1996;22 Suppl 1:i-iv, 1-50, i-iv, 1-55
Whitaker JA, Mirtskhulava V, Kipiani M, et al. Prevalence and incidence of latent tuberculosis infection in georgian healthcare workers. PLoS ONE 2013;8:e58202
Khanna S, Shin A, Kelly CP. Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2017;15:166-174
Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539-1548
Monaghan TM, Cockayne A, Mahida YR. Pathogenesis of Clostridium difficile infection and its potential role in inflammatory bowel disease. Inflamm Bowel Dis. 2015;21:1957-1966
Friedman ND, Pollard J, Stupart D, et al. Prevalence of Clostridium difficile colonization among healthcare workers. BMC Infect Dis. 2013;13:459
Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455
Carmeli Y, Venkataraman L, DeGirolami PC, et al. Stool colonization of healthcare workers with selected resistant bacteria. Infect Control Hosp Epidemiol. 1998;19:38-40
Hell M, Sickau K, Chmelizek G, et al. Absence of Clostridium difficile in asymptomatic hospital staff. Am J Infect Control. 2012;40:1023-1024
van Nood E, van Dijk K, Hegeman Z, et al. Asymptomatic carriage of Clostridium difficile among HCWs: do we disregard the doctor? Infect Control Hosp Epidemiol. 2009;30:924-925
Kato H, Kita H, Karasawa T, et al. Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J Med Microbiol. 2001;50:720-727
Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857-2865
Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis. 2004;10:85-90
Fries W, Cottone M, Cascio A. Systematic review: macrophage activation syndrome in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1033-1045
Stefanescu C, Allez M, Cadiot G, et al. hemophagocytic syndrome during inflammatory bowel disease (IBD): a serious and unfamiliar complication of immunosuppressive therapy. Gastroenterology. 2013;144:S771-S772
Serrate C, Silva-Moreno M, Dartigues P, et al. Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. Inflamm Bowel Dis. 2009;15:1449-1451
Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240-248
Kantsø B, Simonsen J, Hoffmann S, et al. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide danish cohort study 1977-2013. Am J Gastroenterol. 2015;110:1582-1587
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711-721
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710
Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147:618-627;e3
Loftus EV, Colombel J-F, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11:400-411
Colombel J-F, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017;66:839-851
Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-SPira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroentérology. 2018;. pii: S0016-5085(18)30445-1. https://doi.org/10.1053/j.gastro.2018.04.012 [Epub ahead of print]